Sierra Summit Advisors LLC Takes Position in Alnylam Pharmaceuticals, Inc. $ALNY

Sierra Summit Advisors LLC bought a new position in shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) during the 1st quarter, HoldingsChannel.com reports. The fund bought 30,298 shares of the biopharmaceutical company’s stock, valued at approximately $10,025,000.

Other hedge funds also recently added to or reduced their stakes in the company. First Horizon Corp grew its stake in shares of Alnylam Pharmaceuticals by 20.7% in the fourth quarter. First Horizon Corp now owns 163 shares of the biopharmaceutical company’s stock worth $65,000 after acquiring an additional 28 shares in the last quarter. Yousif Capital Management LLC boosted its holdings in Alnylam Pharmaceuticals by 1.8% in the fourth quarter. Yousif Capital Management LLC now owns 1,676 shares of the biopharmaceutical company’s stock valued at $666,000 after purchasing an additional 29 shares during the period. Daiwa Securities Group Inc. grew its stake in Alnylam Pharmaceuticals by 0.3% during the 2nd quarter. Daiwa Securities Group Inc. now owns 12,941 shares of the biopharmaceutical company’s stock worth $4,220,000 after purchasing an additional 35 shares in the last quarter. Golden State Wealth Management LLC increased its holdings in Alnylam Pharmaceuticals by 100.0% during the 4th quarter. Golden State Wealth Management LLC now owns 72 shares of the biopharmaceutical company’s stock worth $29,000 after purchasing an additional 36 shares during the period. Finally, Everpar Advisors LLC raised its position in Alnylam Pharmaceuticals by 6.3% in the 4th quarter. Everpar Advisors LLC now owns 620 shares of the biopharmaceutical company’s stock valued at $247,000 after purchasing an additional 37 shares in the last quarter. 92.97% of the stock is currently owned by institutional investors and hedge funds.

Alnylam Pharmaceuticals Trading Up 3.7%

Shares of Alnylam Pharmaceuticals stock opened at $312.78 on Friday. The company has a fifty day simple moving average of $295.46 and a 200-day simple moving average of $328.42. Alnylam Pharmaceuticals, Inc. has a 12-month low of $273.11 and a 12-month high of $495.55. The company has a current ratio of 3.13, a quick ratio of 3.06 and a debt-to-equity ratio of 0.94. The stock has a market cap of $41.76 billion, a price-to-earnings ratio of 85.46 and a beta of 0.27.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 EPS for the quarter, topping the consensus estimate of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The firm had revenue of $1.17 billion for the quarter, compared to analyst estimates of $1.12 billion. During the same period last year, the business earned ($0.44) EPS. Alnylam Pharmaceuticals’s revenue for the quarter was up 96.4% compared to the same quarter last year. On average, equities analysts forecast that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Insider Activity

In other news, Director David E. I. Pyott sold 3,830 shares of Alnylam Pharmaceuticals stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $299.18, for a total transaction of $1,145,859.40. Following the sale, the director owned 1,582 shares in the company, valued at approximately $473,302.76. The trade was a 70.77% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Melissa Mclaughlin sold 2,286 shares of the business’s stock in a transaction dated Monday, April 6th. The shares were sold at an average price of $330.42, for a total value of $755,340.12. Following the completion of the sale, the insider directly owned 9,443 shares of the company’s stock, valued at $3,120,156.06. The trade was a 19.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Company insiders own 0.86% of the company’s stock.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Wall Street analysts now see significant upside for Alnylam, with a recent report highlighting an average price target of $436, which suggests confidence in the stock’s longer-term growth potential.
• Positive Sentiment: HC Wainwright reiterated a Buy rating and a $470 price target, even while trimming some near-term earnings estimates, signaling that the firm still expects strong multi-year earnings growth for ALNY.
• Positive Sentiment: Komodo Health expanded its strategic partnership with Alnylam, extending work on Komodo’s Healthcare Map and Marmot analytics AI platform. The collaboration may support Alnylam’s data and AI-driven development efforts and reinforces the company’s commercial and operational execution. Article Title
• Neutral Sentiment: HC Wainwright lowered earnings estimates for Q2, Q3, Q4, FY2026, FY2027, FY2028 and FY2029, but also raised its FY2030 estimate. The revisions suggest some near-term caution, offset by optimism about Alnylam’s longer-term earnings trajectory.

Analyst Ratings Changes

A number of equities analysts have recently commented on ALNY shares. Wells Fargo & Company boosted their price objective on Alnylam Pharmaceuticals from $376.00 to $377.00 and gave the stock an “equal weight” rating in a research report on Friday, May 1st. Jefferies Financial Group reiterated a “hold” rating and issued a $330.00 price target (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. HC Wainwright lowered their price target on shares of Alnylam Pharmaceuticals from $510.00 to $470.00 and set a “buy” rating for the company in a report on Monday. Weiss Ratings raised shares of Alnylam Pharmaceuticals from a “sell (d+)” rating to a “hold (c-)” rating in a research report on Monday, May 4th. Finally, Truist Financial dropped their price objective on shares of Alnylam Pharmaceuticals from $515.00 to $505.00 and set a “buy” rating on the stock in a research report on Monday, April 13th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and six have assigned a Hold rating to the company. Based on data from MarketBeat.com, Alnylam Pharmaceuticals currently has an average rating of “Moderate Buy” and a consensus target price of $461.39.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.